Latest News and Press Releases

LIDDS has successfully completed another preclinical study in mice assessing the feasibility of using the NanoZolid® drug delivery technology for intratumoral immunotherapy. Clear anti-tumor effects...

LIDDS has successfully completed the first steps in one of its projects assessing the feasibility of using the NanoZolid® drug delivery technology for intratumoral immunotherapy with positive...

An external analysis concludes that a five years patent extension is expected in Europe and predicts a similar extension procedure in the US provided that the pharmaceutical substances in NanoZolid...

LIDDS has started four internal projects that focus on assessing the feasibility of using the NanoZolid® drug delivery technology for local or intratumoral immunotherapy. These feasibility studies...

LIDDS has received approval from the Indian patent office for its patent on "Method for treatment of prostate cancer and other prostate diseases" with the NanoZolid® drug delivery technology...

JULI - SEPTEMBER 2017 Nettoomsättningen uppgick till 0,2 (0,0) KSEK Kostnaderna uppgick till 1,5 (1,6) MSEK Resultatet före och efter skatt uppgick till -1,5 (-1,6) MSEK Resultat per aktie...

LIDDS has entered a research collaboration with the Department of Laboratory Medicine at Karolinska Institute, Sweden. The collaboration regards fundamental preclinical studies on formulations based...

LIDDS has today launched a newly designed website that will better reflect the ongoing company activities and the NanoZolid® project development pipeline. At the same time the web address is changed...

LIDDS har i en preklinisk modell av aggressiv cancer visat att cytostatika som inkorporerats i NanoZolid® och som injicerats lokalt i tumörer, kan förstärka effekten av systemisk immunterapi. En...

LIDDS har i en preklinisk modell av aggressiv cancer visat att cytostatika som inkorporerats i NanoZolid® och som injicerats lokalt i tumörer, kan förstärka effekten av systemisk immunterapi. En...